CCR5 as a treatment target in pulmonary arterial hypertension. - Wikidata - awgldk - TriplyDB

CCR5 as a treatment target in pulmonary arterial hypertension.

CCR5 as a treatment target in pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q42020850

about

Endogenous Sulfur Dioxide: A New Member of Gasotransmitter Family in the Cardiovascular System Maraviroc: a review of its use in HIV infection and beyond Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and pro-angiogenic therapeutics.The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes.Bone Marrow-derived Cells Contribute to the Pathogenesis of Pulmonary Arterial Hypertension.Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancer-associated fibroblast accumulation.HIV-associated pulmonary arterial hypertension: from bedside to the future.Novel Targets of Drug Treatment for Pulmonary Hypertension.Maintaining lung health with longstanding HIV.Pharmacological treatment of HIV-associated pulmonary hypertension.Non-infectious pulmonary disorders in HIV.Extracellular Calpain/Calpastatin Balance Is Involved in the Progression of Pulmonary Hypertension.Off-label use of maraviroc in clinical practice.The HIV co-receptor CCR5 regulates osteoclast function.Emerging Therapeutics in Pulmonary Hypertension.A Time- and Compartment-Specific Activation of Lung Macrophages in Hypoxic Pulmonary Hypertension.Dynamic and Diverse Changes in the Functional Properties of Vascular Smooth Muscle Cells in Pulmonary Hypertension.Roles for the CX3CL1/CX3CR1 and CCL2/CCR2 Chemokine Systems in Hypoxic Pulmonary Hypertension.Macrophage Regulation during Vascular Remodeling: Implications for Pulmonary Hypertension Therapy.Macrophage Immunomodulation: The Gatekeeper for Mesenchymal Stem Cell Derived-Exosomes in Pulmonary Arterial Hypertension?

P2860

Q26770047-45DB5690-D481-4982-B82B-960A987168DB Q26778504-938521BD-49B6-49F0-9EB4-84D245A2B616 Q30278668-14DFF8AC-EEAC-4885-B763-ADC10A5F2716 Q35115789-9E49705C-FB3E-4E57-8B78-09D45844CA34 Q36847595-3EEC251D-D10F-45E2-A5BD-3C361FBDD219 Q37565466-04EBBC1B-8C57-4134-9CE0-BE0C85E97404 Q38365222-B5054F99-3A4A-42FF-9C66-225328BA94AA Q38504399-80BA9926-069D-45AA-8885-48650CA0E89D Q38629654-AC5030FB-440D-4978-A9B4-CD9F5B2714EF Q38728500-FFC3000E-2C9F-4F44-92D3-1B236A0CFC5E Q39106214-750CA77A-B2E9-4E30-8D4D-40A28F3E687D Q40855297-1AA2F77C-BAB5-49AB-AAFF-58C323B52A34 Q42654565-81691ED0-B46B-43E2-8E81-C75D41A88E50 Q47126167-8D94F0FC-9C67-48DF-A8C8-F47EEE9D1903 Q47700134-B33950E1-C3D6-4BA9-B478-D2080DB3E916 Q48150398-F10FDD4F-6A9A-4E0C-BA57-E81A2C5B1BD0 Q49552882-2F25E148-1B77-4FEA-8A09-B0DB6DA08D84 Q51167771-A4CCC221-1F1A-441D-B478-F10D1E5BDD07 Q52874552-DD2BFB9D-09B3-47F7-99B4-C4AE96E6D9FA Q58700113-B180533F-606D-44BD-A913-D1358D163C91

P2860

CCR5 as a treatment target in pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q42020850

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

CCR5 as a treatment target in pulmonary arterial hypertension.

@en

CCR5 as a treatment target in pulmonary arterial hypertension.

@nl

type

label

CCR5 as a treatment target in pulmonary arterial hypertension.

@en

CCR5 as a treatment target in pulmonary arterial hypertension.

@nl

prefLabel

CCR5 as a treatment target in pulmonary arterial hypertension.

@en

CCR5 as a treatment target in pulmonary arterial hypertension.

@nl

P1433

Q42020850-BC123E2F-505B-4733-8B47-6D0FD44C28A8

P1476

Q42020850-676607C3-8225-46EC-A5E6-0C382B299FE6

P2093

Q42020850-05ADF02A-7A16-4C38-B88F-5EFC5F96A4FB

Q42020850-21B1CD88-3C3D-4A10-BE57-D8A4F55CE995

Q42020850-2708A735-BE6D-4611-AE5A-A82E9D4838CF

Q42020850-58E67C06-C1AA-4B9A-BC5E-369636D51CE7

Q42020850-681E6709-7502-4A91-B5DE-CA3AA751C787

Q42020850-68B25BB2-7A48-4BB8-8DC7-546C8388F1C5

Q42020850-77961E4B-7DC1-40A3-8B04-BAF0F4422A15

Q42020850-7DB1D9A0-7431-49F0-A84A-BC8F50824F35

Q42020850-7E4E133E-1940-471B-8F32-BF46CFA77103

Q42020850-89A4D163-1F1C-4FA9-B6E5-380D529FC280

P2860

Q42020850-0BA39562-501F-44C6-A717-BE5F8181FCB3

Q42020850-1180BA94-F4B6-4BAE-A666-2F1A81005623

Q42020850-18CCC66E-4735-4838-8F9D-1CC446CB9D0A

Q42020850-1FEB0377-8753-43E7-91DE-10C1621956C6

Q42020850-228EB011-F81E-43BE-8E5E-28CF0EA09E1D

Q42020850-38D9C52F-35FF-4A46-A070-8CC2E56B05C0

Q42020850-40E84DDF-28C4-464B-AB18-59C73241D099

Q42020850-687A22A3-BFFA-4FDB-96E4-3CEEF83AFF28

Q42020850-68ECEE24-3C72-4E0C-A619-1F35E09DAE30

Q42020850-6FE6743C-EAE0-431D-8989-79BA8EF62A04

P304

Q42020850-B3D09291-6503-4A30-8A92-34A3B337B2C0

P31

Q42020850-0D7D0BAE-BE08-4B2E-A60E-971D9312EAA6

P356

Q42020850-AF29761E-F4C2-4413-AF4E-06782062B8A6

P407

Q42020850-C76662D2-92AF-4322-8918-4433BE23F5C6

P433

Q42020850-F699ED95-9BF5-47CC-A474-C8D86AAF60D7

P478

Q42020850-8F062D95-54E0-4EE1-8DDC-C5C85216D664

P50

Q42020850-044D1A3C-F2DA-4D23-926F-68366151EB65

Q42020850-4B40A9A4-A9E7-427D-B849-F1F6FA0B9BB6

Q42020850-5BE17AA8-DFE2-43BA-8AB2-5965FE6150C7

Q42020850-6DBBB158-6A5B-42A5-B491-B81D39651EF1

Q42020850-C6FB5A74-DC5B-4F2A-9070-A7B32845AA49

P577

Q42020850-089A03C8-0578-4F5B-9D0C-3F76859EE6F3

P698

Q42020850-C935C583-B4BA-4D13-B2A1-9AEF5FCCECBA

P932

Q42020850-406EFC7E-D2B4-4D37-A2DE-9A482A091383

P356

CIRCULATIONAHA.114.010757

P1433

P1476

CCR5 as a treatment target in pulmonary arterial hypertension.

@en

P2093

Amal Houssaini

http://www.w3.org/2001/XMLSchema#string

Aurélien Parpaleix

http://www.w3.org/2001/XMLSchema#string

Christophe Combadière

http://www.w3.org/2001/XMLSchema#string

Elisabeth Marcos

http://www.w3.org/2001/XMLSchema#string

Karen A Norris

http://www.w3.org/2001/XMLSchema#string

Lucie Poupel

http://www.w3.org/2001/XMLSchema#string

Marion Delcroix

http://www.w3.org/2001/XMLSchema#string

Mirna Saker

http://www.w3.org/2001/XMLSchema#string

Nathalie Mouraret

http://www.w3.org/2001/XMLSchema#string

Rozenn Quarck

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a major co-receptor for primary isolates of HIV-1

HIV-1 entry inhibitors: recent development and clinical use

Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

The many roles of chemokines and chemokine receptors in inflammation

Updated clinical classification of pulmonary hypertension.

Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms.

Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats.

Human immunodeficiency virus transgenic rats exhibit pulmonary hypertension

Pivotal role of the CCL5/CCR5 interaction for recruitment of endothelial progenitor cells in mouse wound healing.

P304

880-891

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.114.010757

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Luc Dubois-Randé

Guillaume Gary-Bobo

Larissa Lipskaia

P577

2014-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24993099

http://www.w3.org/2001/XMLSchema#string

P932

4160408

http://www.w3.org/2001/XMLSchema#string